Cadila Healthcare’s Nether Pharmaceuticals has received its first ANDA approval from the USFDA to market Dextroamphetamine IR Tabs. Nether Pharmaceuticals is a subsidiary of Zydus Pharmaceuticals USA. The drug falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Nesher. The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sale for Dextroamphetamine IR Tabs is $40.6 mn as per IMS.
Nesher has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances, which otherwise cannot be imported.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
